The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Drug Safety: Fasinumab Evaluated in Clinical Trials, Plus Celecoxib May Not Pose Increased Heart Attack or Stroke Risk

Drug Safety: Fasinumab Evaluated in Clinical Trials, Plus Celecoxib May Not Pose Increased Heart Attack or Stroke Risk

May 15, 2018 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

After an independent review, ongoing clinical trials investigating the safety of fasinumab for treating hip or knee osteoarthritis (OA) will discontinue the use of higher fasinumab doses. In other news, a U.S. Food and Drug Administration (FDA) advisory committee has stated celecoxib does not pose an increased heart attack or stroke risk compared with ibuprofen or naproxen.

You Might Also Like
  • Rheumatology Drug Updates: Celecoxib and Cardiovascular Safety Trial Results Reviewed
  • Celecoxib & Cardiovascular Death: NSAID Safety Under Review
  • Ibuprofen More Likely to Raise BP than Naproxen or Celecoxib
Explore This Issue
June 2018
Also By This Author
  • FDA Approves Rituximab Biosimilar; Plus New Safety Data for Filgotinib in RA Patients

Clinical Trial Changes for Fasinumab
Regeneron Pharmaceuticals is currently investigating fasinumab, an antibody that targets nerve growth factor, for treating patients with knee or hip osteoarthritis (OA).1 The treatment is also being studied in patients with chronic low back pain with concomitant knee or hip OA.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

An independent data monitoring committee has been reviewing the ongoing safety and efficacy of fasinumab during clinical trials. The committee recommended that the higher dose fasinumab regimens in the Phase 3 clinical trials be discontinued based on the risk benefit assessment.2 The clinical trial program may continue with lower dose regimens. Thousands of patients have already been enrolled in these trials. The clinical trials are being modified to reflect these recommendations.

Celecoxib Safety Update
In late April, an FDA Advisory Committee stated that celecoxib (Celebrex) poses no increased heart attack or stroke risk compared with patients who took prescription doses of ibuprofen or naproxen.3

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

This conclusion comes after a two-day hearing during which the committee reviewed the results of a study with more than 24,000 patients with rheumatoid arthritis (RA) and OA. The study investigated the safety of celecoxib compared with ibuprofen or naproxen, during which one-third of patients each took one of the three drugs. Based on the committee’s conclusions, the FDA may change its advice for doctors about the drug’s safety. Although the FDA does not have to follow the advisory committee’s advice, it usually does.

The advisory committee vote was 15-5, with one abstention. Many of the committee members noted that celecoxib is not completely safe. The study showed it can increase the possibility of developing cardiovascular complications. However, celecoxib did not appear to increase the risk of cardiovascular complications as much as other non-steroidal anti-inflammatory drugs (NSAIDs)—particularly NSAIDs that are no longer on the market, such as rofecoxib (Vioxx). Nor did celecoxib increase the risk of cardiovascular complications as much as prescription doses of ibuprofen and naproxen, which were thought to be safer.

The study found the risk of death, stroke or having a myocardial infarction among celecoxib-treated patients was 2.3% during a 30-month period vs. 2.5% for naproxen-treated patients and 2.7% for ibuprofen-treated patients. Other adverse events were discussed, such as those related to the gastrointestinal tract (e.g., ulcers, bleeding) and kidney dysfunction. However, a specific vote was not taken related to these adverse events, and some committee members questioned the significance of these results.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 | Single Page

Filed Under: Drug Updates, Safety Tagged With: celecoxib, Drug Safety, fasinumab, FDA, hip, knee, Knee Osteoarthritis (OA), Nonsteroidal anti-inflammatory drugs (NSAIDs), Pain, Pain Management, U.S. Food and Drug Administration (FDA)Issue: June 2018

You Might Also Like:
  • Rheumatology Drug Updates: Celecoxib and Cardiovascular Safety Trial Results Reviewed
  • Celecoxib & Cardiovascular Death: NSAID Safety Under Review
  • Ibuprofen More Likely to Raise BP than Naproxen or Celecoxib
  • Osteoarthritis Treatments: Monoclonal Antibody Starts Clinical Trial & Fasinumab Promising for Treating Pain

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.